Results 51 to 60 of about 35,708 (229)

Chronic cerebrovascular diseases: pathogenetic heterogeneity and therapeutic strategies

Медицинский совет, 2018
The article presents a modern view of the pathogenic mechanisms of cerebrovascular diseases was Observed that currently available data indicate the existence of different variants of ischemic lesions of the brain and their clinical manifestations.
E. V. Kostenko, M. A. Eneeva
doaj   +1 more source

Calcium dobesilate – a perfect stranger

Амбулаторная хирургия, 2020
Pharmacotherapy plays a key role in the treatment of chronic venous diseases and their complications. This category of patients traditionally uses a variety of phlebotropic drugs, the vast majority of which are of plant origin, introducing specific ...
V. Yu. Bogachev, B. V. Boldin, S. V. Rodionov, O. V. Dzhenina   +3 more
doaj   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

British Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed, Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi   +13 more
wiley   +1 more source

Association between daily steps, diabetes management and health indicators in people living with type 1 diabetes: A cross‐sectional study from the BETTER registry

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims In people with type 1 diabetes, physical activity provides important health benefits but is mainly limited by fear of hypoglycaemia. Daily step count is a simple indicator of ambulatory activity. This study examined associations between step count and health indicators.
Thélo I. Garré, Capucine G. Guédet, Laure Alexandre‐Heymann, Virginie Messier, Valérie Boudreau, Semah Tagougui, Claude Laforest, Anne‐Sophie Brazeau, Rémi Rabasa‐Lhoret, Jane E. Yardley   +9 more
wiley   +1 more source

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source

Limited cutaneous systemic sclerosis with myositis showing drug‐induced liver injury and thrombotic microangiopathy [PDF]

, 2023
Hiraku Kokubu, Yudai Tsukamoto, Toshifumi Takahashi, Yoshinao Muro, Noriki Fujimoto   +4 more
openalex   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

MicroRNAs in Systemic Sclerosis: Involvement in Disease Pathogenesis and Potential Use as Diagnostic Biomarkers and Therapeutic Targets

Biomedicines
Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disorder characterized by three main pathological features: microangiopathy, immunological alterations, and excessive synthesis of extracellular matrix (ECM) proteins, leading to fibrosis
Russka Shumnalieva, Simeon Monov, Tsvetelina Velikova   +2 more
doaj   +1 more source

A Rare Case of Gemcitabine-Induced Thrombotic Microangiopathy (TMA) in the Treatment ofMetastatic Nasopharyngeal Carcinoma, presenting to Nephrology Division Khyber TeachingHospital, Peshawar [PDF]

, 2023

openalex   +1 more source

Ocular markers of microangiopathy and their possible association with cardiovascular risk in patients with systemic inflammatory rheumatic diseases: a systematic review

Frontiers in Immunology
Individuals with autoimmune rheumatic diseases (ARDs) are at a higher cardiovascular (CV) risk due to systemic inflammation, which contributes to endothelial dysfunction, atherosclerosis, and structural changes in the vessel walls. Along with traditional
Bengta Sturm, Anna-Lena Zang, Julia Stingl, Rebecca Hasseli-Fräbel, Antonis Fanouriakis, Andreas Schwarting, Andreas Schwarting, Christian Geber, Julia Weinmann-Menke, Mohammed Alhaddad, Konstantinos Triantafyllias, Konstantinos Triantafyllias   +11 more
doaj   +1 more source